Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., trading under the ticker ESLA, is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC business combination and operates in the immunotherapy and oncology sector. The company filed an 8-K current report with the SEC on July 19, 2023, under accession number 0001213900-23-058024, disclosing a material corporate development consistent with its post-merger reporting obligations. Estrella Immunopharma focuses on developing novel cell therapies targeting hematologic malignancies, positioning itself within the broader immuno-oncology space that has attracted significant SPAC deal activity in recent years. For complete filing history, deal terms, sponsor details, and real-time status tracking on ESLA and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.